Novartis’s Iptacopan Pulls Ahead In Race To Fill Nephrology Unmet Need
Phase II Trial In Rare Kidney Disease Is A Success
The first-in-class candidate met two primary endpoints in a Phase II trial for C3 glomerulopathy, suggesting potential edge over ChemoCentryx and Vifor’s competitor avacopan.
